Inhibiting JAK2 and STAT3 expression both suppressed STAT3 activation and reduced the expression of VEGF and bFGF in non-small-cell lung cancer (NSCLC) [65]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.